Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

Zydus Lifesciences is targeting double-digit revenue growth for the fiscal year 2026, driven by robust performance in its ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Consolidated revenue from operations rose 18% YoY to Rs 6528 crore, while EBITDA surged 30% to Rs 2,126 crore, with margins ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

Citi sees margins as a positive surprise in Torrent Pharma Ltd. during the quarter ended March, and forecasts that the ...

Indian drugmaker Zydus Lifesciences reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market.

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

The consolidated net profit of Zydus Lifesciences Ltd for the fourth quarter of financial year 2025 dropped marginally to ...

Zydus Wellness Ltd (BOM:531335) reports robust quarterly performance with significant growth in personal care and food segments, while addressing market challenges and future strategies.